Tech News Summary:
- Charles Dadswell has been appointed as the interim CEO of biotech company Illumina, following the departure of former CEO Francis deSouza earlier this year.
- Dadswell previously served as Illumina’s CFO and brings extensive experience in finance and operations.
- Illumina’s board is confident that Dadswell is the right person to lead the company during this transitional period, as the company continues to push forward with new product launches and collaborations with other industry leaders.
Illumina, a leading name in the field of gene sequencing, has appointed Mark Dadswell as its interim CEO. Dadswell takes over from outgoing CEO Francis deSouza, who announced his departure from the company in May.
Dadswell has been with Illumina for over a decade and has held several executive positions at the company. He most recently served as the senior vice president of Illumina’s Global Operations. In his new role, Dadswell will be responsible for leading the company’s strategic direction and driving growth.
“I am honored and excited to lead Illumina during this interim period,” Dadswell said in a statement. “Illumina’s technology is revolutionizing the way we understand and treat disease, and I look forward to continuing our mission to improve human health by unlocking the power of the genome.”
Illumina’s gene sequencing technology has been instrumental in advancing research into genetic disorders, cancer, and other diseases. The company’s products are used by scientists, researchers, and healthcare providers around the world.
“We are confident that Mark’s extensive experience and leadership will ensure that Illumina continues to drive innovation and expand its global reach,” said Bill Rastetter, Illumina’s chairman of the board.
Dadswell’s appointment comes at a critical time for Illumina, as the company faces continued competition in the gene sequencing market. However, with its cutting-edge technology and strong leadership, Illumina is well-positioned to maintain its position as a leader in the field.